Clinical trials recruiting for Relapsing Multiple Sclerosis
11
Recruiting trials
40
US states with sites
22
Countries
0%
Accept healthy volunteers
Phase breakdown
Drugs and treatments being studied
| Intervention | Trials |
|---|---|
| Ublituximab | 2 |
| Best Available Therapy (BAT) | 1 |
| Fenebrutinib | 1 |
| Fingolimod | 1 |
| Ocrelizumab | 1 |
| Ozanimod | 1 |
| Remibrutinib oral treatment | 1 |
| rapcabtagene autoleucel (YTB323) | 1 |
Where trials are recruiting (top US states)
| State | Recruiting trials |
|---|---|
| California | 5 |
| Massachusetts | 5 |
| North Carolina | 5 |
| Ohio | 5 |
| Colorado | 4 |
| Illinois | 4 |
| Michigan | 4 |
| New York | 4 |
| Tennessee | 4 |
| Texas | 4 |
| Virginia | 4 |
| Wisconsin | 4 |
Top cities
Cleveland, Ohio 5Boston, Massachusetts 4Cincinnati, Ohio 4Milwaukee, Wisconsin 4Aurora, Colorado 3Chicago, Illinois 3Dallas, Texas 3Knoxville, Tennessee 3Las Vegas, Nevada 3New York, New York 3
Self-screener
Recruiting trials
- A NIS Evaluating Various Injectable and Oral Treatments in Patients With Relapsing Multiple Sclerosis
- A Pharmacokinetics (PK), Pharmacodynamics (PD), Safety and Tolerability Study of Fenebrutinib in Children and Adolescents With Relapsing Multiple Sclerosis (RMS)
- A Study Evaluating the Presence and Concentration of BRIUMVI™ (Ublituximab) in Breast Milk
- A Study Evaluating the Real World Experience of Participants Treated With BRIUMVI® (Ublituximab-xiiy) for Relapsing Multiple Sclerosis (RMS)
- An Open-label Study to Assess the Safety, Efficacy, and Cellular Kinetics of YTB323 in Relapsing Multiple Sclerosis
- Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
- Efficacy and Safety of Remibrutinib After Switching From Ocrelizumab in Participants Living With Relapsing Multiple Sclerosis.
- Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study
- Prospective Evaluation of Sequencing From antiCD-20 Therapies to Ozanimod
- Study to Assess Effects of Ublituximab in Pediatric Participants With Relapsing Forms of Multiple Sclerosis
- Study to Evaluate Safety, Efficacy and Pharmacokinetics (PK) of a Modified Regimen of Ublituximab
Related conditions
Trials recruiting for Relapsing Multiple Sclerosis often also study these conditions. Each links to its own recruiting-trial list.
Multiple sclerosis 445Secondary Progressive Multiple Sclerosis 3Relapsing Remitting Multiple Sclerosis 9
Common questions
Are these trials free to join?
Study-related care in a clinical trial is usually provided at no cost to participants, and some trials reimburse travel. Costs vary by study - the trial team will explain what is and is not covered. Confirm this directly with them.
How do I know if I am eligible for Relapsing Multiple Sclerosis trials?
Each trial lists inclusion and exclusion criteria. The screener above checks stated age and sex only. The full eligibility (your medical history, current medications, test results) is assessed by the study team. Open any trial to read its criteria, then contact the site.
Is this list complete?
No. For the full list, search ClinicalTrials.gov.